Last C$0.25 CAD
Change Today 0.00 / 0.00%
Volume 30.8K
MOM On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 11:20 AM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

miraculins inc (MOM) Snapshot

Open
C$0.25
Previous Close
C$0.25
Day High
C$0.25
Day Low
C$0.25
52 Week High
12/31/13 - C$0.50
52 Week Low
06/9/14 - C$0.09
Market Cap
5.0M
Average Volume 10 Days
157.4K
EPS TTM
C$-0.18
Shares Outstanding
20.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MIRACULINS INC (MOM)

Related News

No related news articles were found.

miraculins inc (MOM) Related Businessweek News

No Related Businessweek News Found

miraculins inc (MOM) Details

Miraculins Inc., a medical diagnostic company, focuses on acquiring, development, and commercialization of non-invasive technologies for unmet clinical needs in Canada. The company's PreVu non-invasive skin cholesterol test, a coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin; and SCOUT DS system, a non-invasive diabetes screening system designed to provide sensitive and convenient method for screening for pre-diabetes and type 2 diabetes based on the presence of diabetes-related biomarkers found in skin. It also develops preeclampsia diagnostic test for preeclampsia, a pregnancy specific disease; and offers testing services. The company was incorporated in 1998 and is headquartered in Winnipeg, Canada.

Founded in 1998

miraculins inc (MOM) Top Compensated Officers

Chief Executive Officer, President and Non In...
Total Annual Compensation: C$247.9K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

miraculins inc (MOM) Key Developments

Miraculins Inc. Plans to File Pre-Submission Documentation with the United States Food and Drug Administration Regarding the De Novo Classification of Scout DS(R) Device

Miraculins Inc. has announced its plans to file pre-submission documentation with the United States Food and Drug Administration (USFDA) regarding the de novo classification of its Scout DS(R) device, as a next step in securing marketing clearance in the United States. The de novo classification process provides a potential pathway to Class I or Class II classification for medical devices for which general controls, or general and special controls, provide a reasonable assurance of safety and effectiveness, but for which there is no legally marketed predicate device. The Scout DS(R) device is the non-invasive and highly-sensitive test designed to measure diabetes related biomarkers in the skin. It does not require a blood draw or fasting and generates a result in as little as 80 seconds. The Scout DS(R) device uses visible light to measure the optical signature of fluorescent biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress.

Miraculins Inc. Executes Definitive Agreement for the Sale and Distribution of Scout DS® Diabetes Screening Devices into China with Catalyn Medical Technologies Limited and Cachet Pharmaceutical Co., Ltd

Miraculins Inc. announced that it has executed a definitive agreement for the sale and distribution of Scout DS® diabetes screening devices into China with Catalyn Medical Technologies Limited. Cachet Pharmaceutical Co., Ltd. has been co-appointed as the exclusive distributor of the Scout DS® devices in Mainland China by Miraculins and Catalyn. The Scout DS® device is the non-invasive and highly-sensitive testing device designed to measure diabetes related biomarkers in the skin to help detect pre-diabetes and type 2 diabetes. It does not require a blood draw or fasting and generates a result in as lit le as 80 seconds. The Scout DS® device uses visible light to measure the optical signature of fluorescent biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Key terms of the agreement include: the term of the agreement is to extend for five years from the date of procurement of CFDA (Chinese Food and Drug Administration) regulatory clearance of the Scout DS® device, subject to minimum Scout DS® device sales orders being met; Miraculins to receive certain upfront and milestone payments; initial minimum guaranteed order for USD 15 million in Scout DS® devices for the first year of the term, confirmed on execution of the Agreement, and to be activated on procurement of CFDA regulatory clearance of the Scout DS® device; subsequent minimum orders for USD 15 million in Scout DS® devices for each of years two, three and four of the term, totaling USD 45 million; subsequent minimum order for USD 30 million in Scout DS® devices in year five of the term; Miraculins to be responsible for leading the CFDA regulatory clearance process and its related costs, with Cachet providing guidance and support as necessary and Miraculins to retain the right to establish programs for ongoing device servicing and maintenance once the Scout DS® devices are sold into the field.

Miraculins Inc. Announces Publication of Results from the ENGINE Study

Miraculins Inc. announced the publication of results from the ENGINE (Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes) study, which highlights the effectiveness of the Company's Scout DS NonInvasive Diabetes Screening Device. The study, which is available online ahead of press publication by the Journal of Clinical and Translational Endocrinology, concluded that the elimination of overnight fasting, the absence of blood, and the rapid, real-time communication of screening results are aspects of noninvasive skin fluorescence spectroscopy (Scout DS measurement) that facilitate opportunistic screening of individuals at risk for type 2 diabetes, while delivering performance that is comparable to fasting plasma glucose and HbA1c testing for detection of abnormal glucose tolerance. The published article is entitled "Noninvasive Skin Fluorescence Spectroscopy for Detection of Abnormal Glucose Tolerance". The ENGINE trial was a prospective, multi-centre study conducted on more than 500 patients at 12 clinical sites in the United States. The purpose of the ENGINE trial was a real-world comparison of Scout DS to fasting plasma glucose (FPG) and HbA1c (glycated hemoglobin) for type 2 diabetes screening, using a 2-hour oral glucose tolerance test (OGTT) as the reference standard. FPG and HbA1c are common laboratory-based diabetes tests. All members of the study cohort were at risk for type 2 diabetes according to the ADA (American Diabetes Association) guidelines and therefore members of the intended-use population for Scout DS. The cohort also had a representative mixture of patient age, sex, ethnicity, and BMI (Body Mass Index).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOM:CN C$0.25 CAD 0.00

MOM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Health Discovery Corp $0.01 USD -0.0021
Imperial Innovations Group PLC 497.50 GBp -2.50
MDxHealth €4.37 EUR -0.085
Myriad Genetics Inc $36.65 USD +0.15
Vermillion Inc $1.99 USD +0.182
View Industry Companies
 

Industry Analysis

MOM

Industry Average

Valuation MOM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 151.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 250.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIRACULINS INC, please visit www.miraculins.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.